Printer Friendly

U.S. BIOSCIENCE FILES FOR APPROVAL OF ETHYOL(R) IN EUROPE

 U.S. BIOSCIENCE FILES FOR APPROVAL OF ETHYOL(R) IN EUROPE
 WEST CONSHOHOCKEN, Pa., Sept. 17 /PRNewswire/ -- U.S. Bioscience, Inc. (AMEX: UBS) announced today that its marketing application for Ethyol, a drug under study as a chemoprotective and radioprotective agent, was formally submitted to the European Community's Committee on Proprietary and Medicinal Products (CPMP) and the health ministries of the individual EC member nations.
 Ethyol has been designated by the CPMP as a high-technology product and, as such, will be reviewed under the Concertation Procedure. A drug that qualifies for review under the Concertation Procedure will receive 10 years of marketing exclusivity in the major markets if approved. Under this procedure, one member nation acts as rapporteur. After reviewing the preclinical and clinical data submitted to the French Ministry of Health in August 1991 and the complete dossier in the European Community format submitted in May 1992, France has agreed to act as rapporteur for this application.
 The proposed indication is protection against the hematologic toxicities of cyclophosphamide and mitomycin-C. Based on the timetable adopted by the CPMP at their September 1992 meeting, all member nations must complete their review on the Ethyol dossier and provide their list of questions to the rapporteur by Dec. 15, 1992.
 Based in West Conshohocken, Pa., U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases. The company's portfolio includes a broad spectrum of cancer drugs, including four products in the late stages of development. One compound, altretamine, is marketed under the name Hexalen(R) in the United State.
 -0- 9/17/92
 /CONTACT: Robert I. Kriebel, senior vice president finance and administration, 215-832-4503/
 (UBS) CO: U.S. Bioscience, Inc. ST: Pennsylvania IN: MTC SU:


SM-LR -- NY009 -- 0451 09/17/92 08:51 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 17, 1992
Words:311
Previous Article:SYNTEX FOURTH QUARTER EPS INCREASE 8 PERCENT TO $.41; FISCAL 1992 EPS INCREASE 11 PERCENT TO $2.10
Next Article:CEL-SCI CORPORATION BOARD OF DIRECTORS ADOPTS STOCKHOLDER RIGHTS PLAN
Topics:


Related Articles
FDA PANEL WITHHOLDS RECOMMENDATION TO APPROVE ETHYOL(R)
MGI PHARMA CHEMOPROTECTIVE (MGI 136) PROGRAM REMAINS ON TRACK; COMPANY COMMENTS ON FDA ADVISORY COMMITTEE MEETING ON ETHYOL(R)
U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)
U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)
SCHERING-PLOUGH AND U.S. BIOSCIENCE
U.S. BIOSCIENCE AMENDS NEW DRUG APPLICATION FOR ETHYOL
U.S. BIOSCIENCE GETS CLEARANCE FOR NEUTREXIN; ADDITIONAL INFORMATION REQUESTED ON ETHYOL
ODAC WITHHOLDS RECOMMENDATION TO APPROVE ETHYOL; U.S. BIOSCIENCE, INC. TO SUPPORT CONTINUED CLINICAL DEVELOPMENT OF ETHYOL
ALZA AND U.S. BIOSCIENCE ANNOUNCE MARKETING AND DISTRIBUTION AGREEMENT FOR ETHYOL(R) IN THE UNITED STATES

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters